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Purpose: The aim of this study was to evaluate the diagnostic accuracy of bi-dimensional (2D) and three-dimensional (3D) 
transvaginal ultrasound (TVUS), hysterosonography (HSSG) and hysteroscopy in the detection of endometrial pathology in 
women treated with tamoxifen (TMX) for breast cancer. 
Methods: Forty-two patients, affected by breast cancer under treatment with TMX, underwent 2D-3D TVUS, HSSG and 
hysteroscopy completed by biopsy, after abnormal findings following a routine 2D TVUS examination.
Results: 3D-TVUS was more accurate than 2D-TVUS in the detection of atrophic endometrium confirmed by biopsy and in the 
detection of endometrial polyps.
HSSG and hysteroscopy detected atrophic endometrium and endometrial polyps significantly better than ultrasound scan. 
Endometrial carcinoma was detected in two cases, and in both HSSG and hysteroscopy were 100% diagnostic.
Conclusion: In TMX treated breast cancer patients, HSSG and hysteroscopy provide more accurate diagnosis than 2D-3D 
ultrasound in the detection of treatment related endometrial lesions.
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Introduction
We considered the evaluation of the diagnostic accuracy regarding 
different procedures for the detection of endometrial pathology in 
women treated with tamoxifen (TMX) for breast cancer. TMX is a 
non-steroidal triphenylene derivate with antiestrogenic properties 
on the breast, as competitive inhibitor of estradiol. The adverse 
effects of TMX could be: retinal changes, osteoporosis, 
atherosclerosis, thromboembolic disorders and endometrial 
stimulation. TMX also has estrogenic effects on endometrium, 
inducing a variety of disorders from cystic glandular atrophy to 
endometrial carcinoma  [1,4,5]. The relative risk of developing 
endometrial cancer, during TMX treatment, increases from 1.5 to 
7.5, and it seems to be correlated to both dose and length of 
treatment. There is no consensus regarding the best approach to 
follow up patients under TMX therapy for the screening of 
endometrial pathologies. Dilatation and curettage has been 
questioned because of morbidity, invasive nature and patients 
discomfort [1].
Transvaginal ultrasonography (TVUS, bi-dimensional [2D], three-
dimensional [3D]) has been proposed as a method for monitoring 
the patients treated with TMX. Using a cut-off of 8-10 mm 
endometrial thickness, the false positive rate becomes 10-15%. 
Hysterosonography (HSSG) and hysteroscopy increase diagnostic 
accuracy of TVUS.
Materials and Methods
92 patients affected by breast cancer and in treatment with TMX, 
were followed up in our Institution from January 2010 to 
November 2017.
Exclusions criteria were: the not continuous and available follow-
up by TVUS, the lack of HSSG or hysteroscopy and biopsy, the not 
regular use of TMX and death occurring during the study. After the 
former criteria were observed, 42 patients were eligible and 
recruited in this study. All patients received TMX 20 mg/day. After 
suspected endometrial lesion at first 2D TVUS examination, 
patients underwent 2D-3D TVUS scans and HSSG, and within 7-25 
days, hysteroscopy and biopsy in day surgery. By means of HSSG, 
the regularity of the endometrial outline and the myometrial 
border were observed and the cavity was examined for any 
intrauterine structure delineated by the fluid.
All procedures followed were in agreement with the ethical 
standards of the committee on human experimentation of the 
institution.
No patient used other hormonal therapy. 
Results
Mean patient age was 56.1 yrs, mean age at breast cancer 
diagnosis was 52.3 yrs and time lapse between diagnosis and 
menopause was 7.1 yrs.
Thirty-four women received TMX for a period longer > 24 months, 
10 women received TMX for a period of 12-24 months and 4 for a 
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period < 12 months. The mean endometrial thickness was 
significantly higher when TMX intake was > 24 months (p<0.01).
3D-TVUS was more accurate than 2D-TVUS in the detection of 
43% of atrophic endometrium confirmed by biopsy and in 45% of 
endometrial polyps. HSSG and hysteroscopy detected atrophic 
endometrium, endometrial polyps and endometrial carcinoma 
better than TVUS (Table 1).
Conclusion
Most postmenopausal patients receiving TMX show TVUS 
abnormalities of the endometrium: the most common finding on 
histology in asymptomatic subjects is an atrophic epithelium. 
Endometrial thickness is greater in TMX-treated patients than in 
controls but there is no evidence of an increase in preneoplastic 
changes [2].
The discrepancy is probably due to specific TMX-associated 
subepithelial changes. HSSG is not as invasive as hysteroscopy; it 
has more acceptable risks [3]. HSSG improves the sensitivity of 
TVUS, in particular, the cystic images that 2D-TVUS referred to 
endometrium, are cystic dilatations external to endometrium. 
HSSG screens patients who need hysteroscopy and hystological 
confirmation of TVUS detected endometrial abnormalities.
Endometrial thickness, measured and studied by TVUS, does not 
have an adequate correlation with endometrial pathologies in 
TMX treated women; HSSG guarantees the assessment almost as 
accurately as reached by hysteroscopy, particularly in cases of 
atrophic endometrium and endometrial polyps.
Table 1. Comparison between diagnosis accuracy of lesions 
by different procedures: TVUS, HSSG Hysteroscopy and 
Histology (n=42).
° in all cases endometrial changes were confirmed by biopsy 
and histology.
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Atrophic 
endometrium
4 
(17%)
10 
(43%)
20 
(86%)
21
 (91%)
23
Endometrial 
polyps
2 
(18%)
5 
(45%)
8 
(72%)
10 
(91%)
11
Endometrial
Hyperplasia
- 2 
(66.6%)
2 
(66.6%)
2 
(66.6%)
3 
Endometrial 
carcinoma
- 1 
(50.0%)
2 (100%) 2 
(100%)
2 
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findings
1 
(33.3%)
2 
(66.6%)
3 
100.0%)
3 
(100.0%)
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